0
On 28 May 2024, the US Food and Drug Administration (FDA) approved Amgen's Bkemv (eculizumab-aeeb), the first biosimilar to AstraZeneca's rare blood disorder treatment Soliris approved in the US.
More >- Home
-
Generics
News
- FDA approves generic teriparatide and levetiracetam
- US generics launch and approval for Dr Reddy’s and Lupin
- Five Chinese companies join UN’s MPP for Covid-19 medicines
- South Korean companies to make generic Bridion and COVID-19 drugs
Research
- Saudi FDA drug approvals and GMP inspections: trend analysis
- Generic medications in the Lebanese community: understanding and public perception
- Community pharmacists’ understanding of generic and biosimilar drugs: Lebanon case study
- Reshaping landscape of Japanese generics market – uncertain future of universal health insurance
-
Biosimilars
News
- FDA approves first eculizumab biosimilar Bkemv for two rare diseases
- EC biosimilar approvals: Omlyclo, Jubbonti/Wyost, and Pyzchiva
- EMA recommends approval of biosimilar bevacizumab Avzivi
- FDA approves first interchangeable aflibercept biosimilars to treat macular degeneration
Research
- Efficacy and safety of the proposed P043 (Zerafil) vs reference omalizumab in allergic asthma
- Tocilizumab and pembrolizumab biosimilar advances for Korean firms
- Unveiling key clinical findings for denosumab biosimilar candidates
- Topline results for Polpharma Biologics’ vedolizumab biosimilar candidate
General
- Biosimilars approved in Europe
- Boehringer Ingelheim to expand access to adalimumab biosimilar
- Challenges and progress in the registration of biosimilars in Latin America
- Canada's path to biosimilar adoption and healthcare accessibility: insights from British Columbia
- MORE EDITORIAL SECTIONS
- Search
